2P3G
Crystal structure of a pyrrolopyridine inhibitor bound to MAPKAP Kinase-2
2P3G の概要
エントリーDOI | 10.2210/pdb2p3g/pdb |
関連するPDBエントリー | 1KWP 1NXK 1NY3 2ONL |
分子名称 | MAP kinase-activated protein kinase 2, 2-[2-(2-FLUOROPHENYL)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE (2 entities in total) |
機能のキーワード | kinase domain, atp-binding, serine/threonine kinase, map kinases, mk-2, mk2, transferase |
由来する生物種 | Homo sapiens (human) |
細胞内の位置 | Cytoplasm : P49137 |
タンパク質・核酸の鎖数 | 1 |
化学式量合計 | 38205.07 |
構造登録者 | |
主引用文献 | Anderson, D.R.,Meyers, M.J.,Vernier, W.F.,Mahoney, M.W.,Kurumbail, R.G.,Caspers, N.,Poda, G.I.,Schindler, J.F.,Reitz, D.B.,Mourey, R.J. Pyrrolopyridine Inhibitors of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK-2). J.Med.Chem., 50:2647-2654, 2007 Cited by PubMed Abstract: A new class of potent kinase inhibitors selective for mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2 or MK-2) for the treatment of rheumatoid arthritis has been prepared and evaluated. These inhibitors have IC50 values as low as 10 nM against the target and have good selectivity profiles against a number of kinases including CDK2, ERK, JNK, and p38. These MK-2 inhibitors have been shown to suppress TNFalpha production in U397 cells and to be efficacious in an acute inflammation model. The structure-activity relationships of this series, the selectivity for MK-2 and their activity in both in vitro and in vivo models are discussed. The observed selectivity is discussed with the aid of an MK-2/inhibitor crystal structure. PubMed: 17480064DOI: 10.1021/jm0611004 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (3.8 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード